{"id":"NCT01328444","sponsor":"GlaxoSmithKline","briefTitle":"An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A","officialTitle":"An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03-01","primaryCompletion":"2012-06-01","completion":"2012-06-14","firstPosted":"2011-04-04","resultsPosted":"2014-02-10","lastUpdate":"2017-10-11"},"enrollment":349,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"GSK 573719 +GW642444 125/25","otherNames":["High Dose Dual"]},{"type":"DRUG","name":"GSK573719 + GW642444 62.5/25","otherNames":["Low Dose Dual"]},{"type":"DRUG","name":"GSK 573719 125","otherNames":["High Dose 719"]},{"type":"DRUG","name":"GSK 573719 62.5","otherNames":["Low Dose 719"]},{"type":"DRUG","name":"GW642444 25","otherNames":["LABA (444)"]},{"type":"DRUG","name":"Plb","otherNames":["Placebo"]}],"arms":[{"label":"GSK 573719 + GW642444 125/25","type":"EXPERIMENTAL"},{"label":"GSK 573719 +GW642444 62.5/25","type":"EXPERIMENTAL"},{"label":"GSK 573719 125","type":"EXPERIMENTAL"},{"label":"GSK 573719 62.5","type":"EXPERIMENTAL"},{"label":"GW 642444 25","type":"EXPERIMENTAL"},{"label":"Plb","type":"PLACEBO_COMPARATOR"}],"summary":"This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444. The primary objective is to evaluate lung function and exercise endurance time after 12 weeks of once-daily administration of GSK573719/GW642444 Inhalation Powder (125/25mcg and 62.5/25mcg), GSK573719 Inhalation Powder (125mcg and 62.5mcg), GW642444 Inhalation Powder 25 mcg and placebo delivered by a Novel dry powder inhaler (Novel DPI)","primaryOutcome":{"measure":"Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period","timeFrame":"Week 12 of each treatment period (up to Study Week 29)","effectByArm":[{"arm":"Placebo","deltaMin":36.7,"sd":13.17},{"arm":"UMEC 62.5 µg QD","deltaMin":63.2,"sd":23.93},{"arm":"UMEC 125 µg QD","deltaMin":49.8,"sd":23.77},{"arm":"VI 25 µg QD","deltaMin":26.7,"sd":19.72},{"arm":"UMEC/VI 62.5/25 µg QD","deltaMin":58.6,"sd":13.82},{"arm":"UMEC/VI 125/25 µg QD","deltaMin":69.1,"sd":13.99}],"pValues":[{"comp":"OG000 vs OG001","p":"0.321"},{"comp":"OG000 vs OG002","p":"0.620"},{"comp":"OG000 vs OG003","p":"0.665"},{"comp":"OG001 vs OG004","p":"0.865"},{"comp":"OG003 vs OG004","p":"0.174"},{"comp":"OG002 vs OG005","p":"0.472"},{"comp":"OG003 vs OG005","p":"0.072"},{"comp":"OG000 vs OG004","p":"0.234"},{"comp":"OG000 vs OG005","p":"0.080"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":17},"locations":{"siteCount":31,"countries":["United States","Bulgaria","Estonia","Germany","Russia","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":170},"commonTop":["Nasopharyngitis","Headache","Sinusitis","Dry mouth"]}}